Showing results (191-200 of 404) with videos related to

Sort By:
Pageof 41
Bone Marrow Transplantation|November 30, 2010
Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCTL Bühlmann, A S Buser, N Cantoni, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplantsA Gratwohl, J Hermans, D Niederwieser, et al.
Dermatology (Basel, Switzerland)|May 2, 2009
Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantationP Haeusermann, E Kump, A Rovó, et al.
Transfusion|August 5, 2000
Preterm birth and the availability of cord blood for HPC transplantationD V Surbek, W Holzgreve, C Steinmann, et al.
Experimental Hematology|January 29, 1999
Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbitsM Pless, A Wodnar-Filipowicz, L John, et al.
Annals of Hematology|February 1, 1993
Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemiaD Nachbaur, A Gratwohl, M Herold, et al.
Schweizerische Medizinische Wochenschrift|October 25, 1986
[12 years' experience in bone marrow transplantation in leukemic patients in Switzerland]A Gratwohl, J Gmür, B Chapuis, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 1989
[Comparative study on in vitro lymphocytotoxicity and mitogenicity of different antilymphocyte globulin (ALG) preparations]Y Kawano, Y Takaue, T Watanabe, et al.
Pharmaceutisch Weekblad. Scientific Edition|June 25, 1982
Cyclosporin A: correlation between HPLC and RIA serum levelsE Abisch, T Beveridge, A Gratwohl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1986
Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemiaL Tschopp, V E von Fliedner, C Sauter, et al.
Pageof 41